3, 3-difluorocyclobutanamine hydrochloride is a key intermediate in the new FDA release of Tibsovo in 2018. Tibsovo is a first-of-its-kind, selective, powerful oral targeted inhibitor for IDH1 mutated cancer that has been approved by the FDA for the treatment of recurrent or refractory acute myeloid leukemia (AML) in adults with specific IDH1 gene mutations.